1 The EIC Accelerator Project

EIC Accelerator Program Overview

The EIC Accelerator program, part of the European Innovation Council (EIC), aims to support small and medium-sized enterprises (SMEs) and startup companies in developing and scaling innovative technologies, particularly within the deep tech sector. This funding initiative addresses the challenges faced by European startups in scaling their innovations and bridging the gap between early-stage development and market entry.

Funding Structure

The EIC Accelerator provides a blended finance model that combines grants and equity investments to support innovative projects. The grant component can reach up to €2.5 million, which is intended to cover research, development, and initial commercialization costs. The equity component is designed to provide additional financial backing; until 2024, it can reach up to €15 million, but this amount has been reduced to €10 million starting from 2025. This flexible funding structure allows companies to tailor their financing to meet specific needs while minimizing reliance on traditional debt financing.

Purpose in the European DeepTech Ecosystem

The EIC Accelerator plays a crucial role in the European deep tech and startup ecosystem by fostering innovation and competitiveness. By providing substantial financial resources and mentorship, the program helps companies navigate the complexities of bringing groundbreaking technologies to market. The initiative encourages collaboration between startups and established companies, facilitating knowledge transfer and enhancing the overall innovation landscape in Europe.

Role in Scaling Companies

The EIC Accelerator's support enables companies to attract additional funding from private sectors, thereby enhancing their growth potential. By providing a solid financial foundation, the program allows startups to focus on product development, market validation, and scaling operations without the immediate pressure of generating revenue. The backing from the EIC also serves as a validation of the technology's potential, making it easier for companies to secure further investment from venture capitalists and other private investors.

EIC Accelerator Winner: Paragate Medical Ltd

Company Overview

Paragate Medical Ltd, based in Israel, has emerged as a notable winner of the EIC Accelerator program. The company focuses on developing advanced medical technologies aimed at addressing significant healthcare challenges. Their project, acronymed FILBERT, represents a transformative approach to managing chronic fluid congestion, a condition that affects numerous patients worldwide.

Project Description: FILBERT

The FILBERT project revolves around the creation of an innovative implantable device and a comprehensive management platform designed to prevent chronic fluid congestion. This condition often leads to serious health complications, including heart failure and other cardiovascular issues. The device aims to provide real-time monitoring and management of fluid levels within the body, thereby allowing for timely interventions and improved patient outcomes.

Technological Background

The underpinning technology of the FILBERT project involves advanced sensor integration and data analytics. The implantable device is designed to continuously monitor fluid levels within the body, utilizing biocompatible materials and state-of-the-art sensor technology. This enables the device to provide accurate, real-time data to healthcare providers and patients alike.

The management platform associated with FILBERT acts as a user-friendly interface, allowing for seamless communication between the device and healthcare professionals. Through the platform, patient data can be monitored remotely, facilitating proactive management of chronic conditions. The integration of artificial intelligence and machine learning algorithms allows for predictive analytics, enhancing decision-making processes in patient care.

Conclusion

The EIC Accelerator program, through its blended finance model, represents a significant opportunity for innovative companies like Paragate Medical Ltd. By supporting projects such as FILBERT, the EIC Accelerator contributes to advancements in healthcare technology that can improve patient outcomes and reshape the medical landscape. The program not only aids in the financial scaling of such innovations but also reinforces Europe's position as a leader in deep tech and medical advancements.

2 The Funding Rounds

Paragate Medical Ltd: Funding and Investment Overview Since EIC Accelerator Award (Jan 2023)

Financing Raised & Funding Rounds

Paragate Medical Ltd, based in Israel, has been active in securing non-dilutive and equity funding rounds from various sources since its inception. The company is a recipient of several significant grants from the European Innovation Council (EIC), including:

• June 2018: EIC Grant of €50,000
• April 2019: EIC Grant of €2 million
• January 2023: EIC Accelerator Grant of €2.5 million

The January 2023 grant corresponds to the company's successful application to the EIC Accelerator program after submitting its Step 2 proposal on January 11, 2023.

In total, publicly reported funding for Paragate Medical stands at approximately $5.79 million across three main rounds. The most recent individual round before or around the latest disclosed data was a $400,000 seed round, though further specifics about this particular round's exact timing and investors are not detailed.

Timing and Amounts of Funding Rounds

Date	Source / Round	Amount
Jun 2018	EIC Grant	€50K
Apr 2019	EIC Grant	€2M
Jan 2023	EIC Accelerator	€2.5M
Not specified (recent)	Seed	$400K

Total cumulative funding as per disclosures is roughly $5.79 million.

Investor Information

The major known investor for Paragate Medical is the European Innovation Council via EU programs focused on supporting high-potential startups in medtech fields. There are two identified investors overall according to public startup databases; however, their names beyond institutional sources like the EU have not been explicitly published as part of these records. Other possible support may have come from Israeli innovation agencies or associated venture partners given their inclusion among “invested companies” by national innovation authorities in Israel as recently as late-2023 listings.

As an alumnus of MedTech Innovator’s acceleration programs, Paragate has also gained access to a network of medtech investors through international demo days and investor forums but specific deal participation details are unavailable within public records post-January 2023.

Company Valuation

No official market capitalization or private valuation figure for Paragate Medical has been disclosed publicly after its most recent fundraising activities—valuation remains "undisclosed" according to multiple investment tracking platforms.

Exit Events: IPOs/Buyouts/Acquisitions

There are no reports indicating that Paragate Medical has undergone an exit event such as an IPO (Initial Public Offering), buyout, or acquisition since receiving its latest round of funding through the EIC Accelerator. The company continues to operate independently with ongoing product development activities listed under medical engineering ventures in Israel's national innovation ecosystem updates through at least late-2024/early-2025 references.

---

Sources

• Paragate Medical company information, funding & investors – Dealroom
• Paragate Medical company information – Startup Estonia
• MedTech Innovator Forum - DeviceTalks Boston
• Paragate Medical - Startup Nation Finder
• Invested Companies - Innovation Authority Israel

3 The Press Releases

Paragate Medical LTD: Overview and Developments

Paragate Medical LTD, based in Israel, is a notable recipient of the European Innovation Council (EIC) Accelerator funding. The company achieved this milestone on January 11, 2023. Since then, Paragate Medical has been focusing on advancing its innovative medical technologies.

Business Focus

Paragate Medical is committed to developing solutions for managing chronic conditions, particularly fluid overload in patients with heart or kidney failure. Their flagship product is the Implantable Peritoneal Ultrafiltration Device (IPUD). This device is designed to continuously remove excess fluid from the body, providing a 24/7 management solution for patients. It serves as a mechanical bypass to the kidneys, allowing patients to maintain fluid balance at home rather than relying on frequent hospital admissions.

Technology and Innovations

The IPUD device is a minimally invasive and fully implantable system that streams collected data to a management platform. This platform enables remote monitoring by physicians, allowing for personalized therapy based on real-time patient data. The technology supports continuous, active treatment of fluid overload, improving patient outcomes by maintaining optimal fluid balance without the need for aggressive interventions.

Funding and Recognition

Paragate Medical's win of the EIC Accelerator funding highlights its potential in the medical technology sector. Additionally, the company has received other notable recognitions, including an honorable mention in the kidneyX phase 1 innovation competition and winning the MAXIS innovation award at the ICI 2017.

Press Releases and Updates

Paragate Medical posts updates and news on its website, including discussions on Israeli innovations in cardiovascular technologies and advancements in fluid management devices. These updates reflect the company's commitment to innovative healthcare solutions.

Team and Partnerships

While specific team updates or new partnerships have not been detailed in recent press releases, Paragate Medical's success in securing the EIC Accelerator funding underscores its potential for collaboration and innovation within the medical technology sector.

Conclusion

Since receiving the EIC Accelerator funding in January 2023, Paragate Medical has continued to develop its groundbreaking IPUD technology. The company remains focused on transforming healthcare by providing continuous, home-based care solutions for patients suffering from chronic fluid overload.

Sources

• Paragate Medical: Home Page
• News Archive - Paragate Medical

4 The Technology Advancements

Current Capabilities and Advancements of Paragate Medical LTD

Paragate Medical LTD, an innovative Israeli company founded in 2016, specializes in developing implantable devices for managing fluid overload in patients with chronic heart and kidney failure. Their flagship product is the Implantable Peritoneal Ultrafiltration Device (IPUD), which acts as a mechanical bypass to the kidneys, continuously removing excess fluid from the body to maintain fluid balance.

Current Capabilities

• IPUD Device: The device is minimally invasive, fully implantable, and operates 24/7 to treat patients. It uses a controlled locking protocol to absorb fluid from the body and drains it into the bladder without interfacing with the heart or circulation.
• Remote Monitoring: The system allows for remote monitoring of patient data, enabling tailored therapy adjustments by physicians.

Advancements Since EIC Accelerator Funding

As of the latest available information, there are no specific details on advancements made by Paragate Medical LTD following their receipt of the EIC Accelerator funding on January 11, 2023. However, the company's broader goals involve shifting heart failure treatment from hospital to home-based care, which could be further supported by such funding.

Technology Improvements and Market Demonstrations

While specific improvements since January 2023 are not detailed, Paragate Medical's technology has been progressing through human clinical trials, with the IPUD device undergoing feasibility trials in Poland and Georgia. The company aims to reduce healthcare costs associated with frequent hospital admissions for heart failure patients, potentially through more efficient home-based care.

New Patents and Scientific Publications

There are no recent updates available on new patents filed or scientific studies published by Paragate Medical LTD in the context of the EIC Accelerator funding. However, their ongoing clinical trials and technological development suggest continued innovation in their field.

Conclusion

Paragate Medical LTD has made significant strides in developing implantable solutions for fluid overload management, with a focus on home-based care. While specific advancements since January 2023 are not detailed in available sources, the company's ongoing clinical trials and potential EIC Accelerator funding could further enhance their technological capabilities and market presence.

Sources

• Paragate Medical: Home Page https://paragate-medical.com
• Invested Companies 2025 - English Innovation Site https://innovationisrael.org.il/en/invested-companies-2025/
• About - Paragate Medical https://paragate-medical.com/about/
• Paragate Medical - Development Aid https://www.developmentaid.org/organizations/view/294660/paragate
• Paragate's implantable tech will make management of heart failure ... https://www.nsmedicaldevices.com/analysis/paragate-medical-management-heart-failure/
• Nitai Hanani, Paragate Medical | LSI Europe '22 https://www.lifesciencemarketresearch.com/videos/nitai-hanani-paragate-medical-implantable-peritoneal-ultrafiltration-device-lsi-europe-22

5 The Partnerships and Customers

Paragate Medical's Strategic Partnerships and Market Positioning Paragate Medical Ltd., an Israel-based medtech company, has advanced its implantable peritoneal ultrafiltration device (IPUD) through clinical development and strategic engagements. While specific customers remain undisclosed, the company's collaborations and trial activities highlight its market trajectory.

• Clinical Collaborations: Paragate is conducting a First-in-Human (FIH) clinical feasibility trial for IPUD in Poland and Georgia, indicating partnerships with medical institutions in these regions. The device’s remote monitoring capabilities suggest integration with healthcare providers adopting telehealth solutions.
• Key Relationships: Duke University’s Marat Fudim lists Paragate among external collaborators, though the nature of this relationship is unspecified. Such academic ties could support clinical validation or research initiatives.
• Purpose of Relationships: These engagements focus on technology validation, scaling trials, and refining IPUD’s management platform to enable continuous home-based fluid removal for heart/kidney failure patients.

Market Positioning and Technology Advancements
By emphasizing home-based care, Paragate aims to reduce hospital readmissions, aligning with payers’ cost-saving priorities. The IPUD system streams real-time data to physicians, positioning the company as a leader in IoT-enabled chronic disease management. Current partnerships likely accelerate regulatory approvals (e.g., CE mark preparation) and enhance credibility for future commercial agreements.

While no new customers or partners are explicitly named post-EIC Accelerator funding (2023), ongoing trials and platform upgrades indicate progress toward broader adoption. Scaling production through contract manufacturing organizations (CMOs) further underscores operational readiness for market entry.

---

Sources

• Paragate Medical: Home Page
• IPUD – Implantable Peritoneal Ultrafiltration Device
• Nitai Hanani Presentation at LSI Europe '22
• Marat Fudim's Collaborations at Duke University

6 The Hiring and Company Growth

Paragate Medical Ltd.: Team Growth and Scaling Post-EIC Accelerator Funding Paragate Medical, an Israel-based medtech company specializing in implantable fluid management solutions for chronic heart and kidney failure, has focused on advancing its minimally invasive IPUD (Implantable Peritoneal Ultrafiltration Device) since its 2016 founding. While specific hiring figures or headcount growth post-2023 EIC Accelerator funding remain undisclosed in available sources, the company’s leadership structure and strategic priorities provide insights into its scaling trajectory.

Team Structure and Key Hires

• Leadership: CEO Nitai Hanani and Medical Director Dr. Yair Feld lead the team, supported by CFO Nizar Mishael and Chairman Zohar Gendler. Clinical Affairs expertise is bolstered by Inbal, whose background includes leading clinical trials at Medtronic.
• Recent Additions: Public details on recent hires are limited, but roles in clinical operations, R&D, and regulatory compliance are likely priorities given the IPUD’s stage of development.

Growth Drivers Post-Funding

The EIC Accelerator funding (awarded January 2023) likely accelerates:

Management Stability

No major changes in founding team composition are reported as of 2025, with Dr. Feld remaining central to medical strategy and Hanani leading operational execution. Advisers like Piotr Ponikowski (cardiology expert) reinforce clinical credibility for European market entry.

Future Trajectory

New hires—particularly in regulatory affairs, data analytics, and patient advocacy—would align with Paragate’s goal of shifting fluid-overload management from hospitals to homes through continuous remote monitoring via the IPUD platform. This positions Paragate as a potential leader in value-based care models for chronic disease management.

---

Sources

Paragate Medical: Home Page | About Us | Invested Companies 2025

7 The Media Features and Publications

Paragate Medical Ltd.: A Leader in Heart and Kidney Failure Treatment

Company Overview

Paragate Medical Ltd., based in Haifa, Israel, is a pioneering medical device company that has been revolutionizing the management of heart failure since its inception in 2016. The company's mission is to reduce fluid overload in patients with chronic heart and kidney failure, a significant burden on the healthcare system. Paragate's innovative solution involves developing the first-ever implantable device, known as the Implantable Peritoneal Ultrafiltration Device (IPUD), which acts as a mechanical bypass to the kidneys, continuously removing excess fluid from the body.

Media Features and Publications

Paragate Medical has been featured in various publications for its groundbreaking work. Notably, the company's IPUD device has been highlighted in medical technology news outlets for its potential to transform the care of heart and kidney failure patients by providing a remote, home-based solution. Additionally, Paragate's participation in conferences such as the LSI Europe '22 Emerging Medtech Summit has further increased its visibility in the medical technology community.

Podcasts and Interviews

Nitai Hanani, CEO of Paragate Medical, was a presenter at the LSI Europe '22 Emerging Medtech Summit, where he discussed the company's innovative device and its implications for patient care.

Conference and Fair Visits

Paragate Medical actively participates in significant medical technology events. For instance, its presence at the LSI Europe '22 Emerging Medtech Summit showcased its commitment to advancing medical device technology and sharing its vision with industry leaders.

Event Involvement

The company's involvement in events like the LSI Europe summit demonstrates its engagement with the broader medtech community, facilitating collaborations and knowledge exchange that are crucial for innovation in the field.

EIC Accelerator Funding

In January 2023, Paragate Medical received the EIC Accelerator funding, a prestigious award that recognizes and supports innovative companies in the European Union. This funding will likely enhance the company's ability to further develop and commercialize its IPUD device, benefiting patients worldwide.

Conclusion

Paragate Medical is at the forefront of medical innovation, addressing critical healthcare challenges through its pioneering IPUD technology. With its focus on home-based care solutions and participation in key industry events, the company is poised to make significant impacts in the management of heart and kidney failure.

---

Sources: - Paragate Medical: Home Page

• About - Paragate Medical
• Paragate Medical Ltd. - F6S
• Paragate Medical - Development Aid
• Paragate Medical Ltd
• Implantable device developed for remote care of heart and kidney failure patients.
• Nitai Hanani, Paragate Medical | LSI Europe '22
• IPUD – An Implantable Peritoneal Ultrafiltration Device